4SC-202

null · 4SC AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 4SC-202, covering 2022-02-04 to 2022-02-04. Get the full timeline:

Most recent: Clinical Trial Update: 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy [Phase 1, Phase 2]

See pricing